2604.01657 FEBRIL-NEUT-MASCC v2: A Transparent Reweighting of the MASCC Score for Contemporary Outpatient Management
FEBRIL-NEUT-MASCC v2: We present a pre-validation composite scoring framework for MASCC-style serious complication endpoint at 30 days in adult solid-tumour and selected haematologic-malignancy patients presenting with febrile neutropenia who are being triaged for outpatient vs inpatient management. Published literature reports MASCC score >=21 identifies low-risk with ~4-6% complication rate; original derivation Klastersky 2000; contemporary cohorts suggest item recalibration warranted [Klastersky 2000; Carmona-Bayonas 2015], with effect sizes for individual modifiers reported inconsistently across study designs and grading conventions.